Table 3.
Characteristics at first presentation and disease progression in severe cases of chronic central serous chorioretinopathy
| Characteristics | Severe manifestation of CSC | Final follow-up visit | p-value |
|---|---|---|---|
| BCVA (ETDRS letters) | 68 ± 19 | 70 ± 22 | 0.061 |
| Eyes with SRF, n (%) | 173 (87) | 47 (24) | <0.001 |
| Eyes with PCRD, n (%) | 69 (35) | 35 (18) | <0.001 |
| CFTa (µm) | 105 ± 31 | 106 ± 30 | 0.930 |
| DARA surfaceb (DD) | 6.3 ± 3 | 9.0 ± 5 | <0.001 |
| Mean number of treatmentsc (range) | n/a | 2.5 (1–20) | n/a |
| Mean number of recurrencesd (range) | n/a | 1.2 (0–9) | n/a |
Notes:
CFT could be measured manually in 63 eyes (32%) with a spectral-domain optical coherence tomography.
In 68 cases (34%), a follow-up FA (at least 1 year later) was available to be compared with baseline FA.
Twenty-six cases (13%) were never treated and were not included in this analysis.
Twenty-one cases (11%) never showed a complete resolution of SRF, and were not included in this analysis. Data presented as mean ± SD unless otherwise indicated. Bold font indicates data were considered statistically significant.
Abbreviations: BCVA, best-corrected visual acuity; CSC, central serous chorioretinopathy; CFT, central foveal thickness; DARA, diffuse atrophic retinal pigment epithelium (RPE) alterations; DD, optic disc diameters; ETDRS, Early Treatment of Diabetic Retinopathy Study; FA, fluorescein angiography; n/a, not applicable; PCRD, posterior cystoid retinal degeneration; SRF, subretinal fluid.